Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
The stream is slated to start at 2:30 pm ETThe Fedread more
This is a comparison of Wednesday's FOMC statement with the one issued on May 1 after the Fed's previous policy-making meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
If you're concerned about what Wednesday's Fed decision means for your bank account, mortgage loan or credit card — as well as student debt, home equity loan and car payment —...Personal Financeread more
The Federal Open Market Committee's quarterly economic forecast includes the so-called dot plot of where members see interest rates heading.The Fedread more
Employees spoke out on issues like forced arbitration, workplace equity and Project Dragonfly at Alphabet's annual shareholder meeting.Technologyread more
The Federal Reserve lowered its inflation forecast for 2019 while keeping the growth expectations unchanged.The Fedread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
U.S. drugmaker AbbVie has announced plans to takeover Dublin-based pharmaceutical company Shire in a deal worth around £32 billion ($54.7 billion), as AbbVie seeks to lower its tax rate by buying a foreign rival.
The Shire board has backed an offer that will be made up of £24.44 in cash and 0.8960 AbbVie share per Shire share, meaning AbbVie will pay about £52.48 per share for the specialist pharmaceutical firm.
Shire shareholders will end up owning 25 percent of the new merged group.
AbbVie said it expects the deal will cut its effective tax rate to approximately 13 percent.
Shire shares were up as much as 2.5 percent shortly after the deal was announced.
If the takeover is successful, North Chicago-based AbbVie plans to relocate the new combined firm in the U.K., allowing it to benefit from the country's lower tax.
Shire is the second FTSE-listed pharmaceutical firm that has been approached by a U.S. rival, after Pfizer's failed takeover bid for U.K. group Astra Zeneca.
The Shire Board, has been advised by Citi, Deutsche Bank, Evercore, Goldman Sachs and Morgan Stanley. Shire said the banks consider the terms of the transaction to be fair and reasonable.
Follow us on Twitter: